Boundless Bio Inc Dossier - Source-backed chat

Boundless Bio Inc

BOLDNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.62

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.59Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $58.9M

Enterprise Value $38.7M

Shares Outstanding 22.5M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Boundless Bio, Inc. (BOLD) is a clinical-stage precision oncology company pioneering a novel therapeutic paradigm by targeting extrachromosomal DNA (ecDNA), a primary driver of oncogene amplification and treatment resistance in up to 40% of metastatic cancers. Following a strategic portfolio review in early 2026, the company streamlined its operations to focus resources on its lead clinical asset, BBI-940, an oral kinesin degrader. BBI-940 entered a Phase 1 first-in-human trial (KOMODO-1) in February 2026 targeting ER+/HER2- and TNBC-LAR breast cancers. Trading at a deep discount to its cash value (market cap of ~$32M vs. ~$92.8M in cash as of Q1 2026), Boundless Bio offers a highly asymmetric risk/reward profile. Its cash runway extends into the second half of 2028, providing ample funding to achieve critical clinical proof-of-concept milestones for BBI-940.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$4.00

High · most bullish analyst$4.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.0020%

BBI-940 encounters dose-limiting toxicities or fails to show meaningful clinical efficacy in the KOMODO-1 trial, mirroring the narrow therapeutic index issues that led to the discontinuation of the company's prior CHK1 inhibitor program (BBI-355). The stock continues to trade below cash value, and the company is forced to seek highly dilutive financing or strategic alternatives as its cash runway depletes.

Base CaseCentral scenario

$4.0050%

Matches the consensus mean

The KOMODO-1 trial progresses steadily, demonstrating acceptable safety, predictable pharmacokinetics, and early signs of clinical activity (stable disease or partial responses) in heavily pretreated breast cancer patients. The cash runway remains secure into 2028, allowing the company to advance BBI-940 through dose escalation and expansion cohorts while validating the ECHO diagnostic tool.

Bull CaseUpside scenario

$8.0030%

BBI-940 demonstrates robust clinical efficacy and a favorable safety profile in the KOMODO-1 trial, showing clear tumor regression in ecDNA+ breast cancer patients. The ECHO diagnostic software successfully identifies and enriches the trial with ecDNA-positive patients, validating ecDNA as a highly druggable precision oncology target. The company secures a high-value strategic biopharma partnership, driving a massive re-rating of the stock toward its historical highs.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class therapeutic approach targeting ecDNA, a validated driver of oncogene amplification and treatment resistance in aggressive solid tumors.
Strong balance sheet with $92.8M in cash and short-term investments as of March 31, 2026, providing a runway into the second half of 2028.
Highly asymmetric valuation, with the company's market capitalization (~$32M) trading at a fraction of its net cash position.
Proprietary ECHO diagnostic software algorithm provides a unique companion diagnostic tool to enrich clinical trials with ecDNA-positive patients.

Key Investment Risks

High clinical development risk, as targeting ecDNA is an unproven therapeutic modality in humans.
History of pipeline setbacks, including the early 2026 discontinuation of prior clinical candidates BBI-355 and BBI-825 due to narrow therapeutic index and strategic prioritization.
Dependence on a single clinical-stage asset (BBI-940), making the company's valuation highly sensitive to KOMODO-1 trial outcomes.
Reliance on third-party contract research organizations (CROs) and manufacturers for clinical trial execution and drug supply.

Thesis Invalidation Triggers

Severe safety signals or dose-limiting toxicities observed in the KOMODO-1 trial of BBI-940.
Failure of BBI-940 to demonstrate reduction or elimination of ecDNA in patient tumor biopsies.
Inability of the ECHO diagnostic software to reliably detect ecDNA-bearing tumors in clinical settings.
Significant acceleration of cash burn rate, shortening the projected runway to under 12 months.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.